Safety and tolerability of Miltuximab® - a first in human study in patients with advanced solid cancers
Objective(s): Miltuximab® is a chimeric antibody targeting Glypican-1 (GPC-1), a cell surface antigen which is overexpressed in solid cancers. Miltuximab® has shown promising safety and efficacy in radioimmunotherapy models of prostate cancer. This first in human study used Miltuximab® radiolabelled...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Mashhad University of Medical Sciences
2021-07-01
|
| Series: | Asia Oceania Journal of Nuclear Medicine and Biology |
| Subjects: | |
| Online Access: | https://aojnmb.mums.ac.ir/article_18091_b4973c069eb12d3a20aec24ad0ceaeb8.pdf |